User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

Interactions with Platform & by Email *

INTERACTIONS

Unique # Participated *

PARTICIPANTS

Responses Validated *

VALIDATIONS

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2  
   Data Interpretation & Reporting Level.....I-3
Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
   Drug Delivery.....I-4
In Vitro Diagnostics.....I-4
In Vivo Imaging.....I-4
Biomaterials.....I-4
Others.....I-4
  
   Introduction.....II-1
Current and Future Analysis.....II-1
Industry Drivers.....II-1
1$100
   Industry Challenges.....II-21$100
   Developing World Ready to Adopt Nanomedicine in a Major Way.....II-3
India.....II-3
1$100
   China.....II-4
Japan.....II-4
Taiwan.....II-4
Nanotechnology Based Medical Products.....II-4
1$100
   Table 1: Global Nanomedicine Market (2007): Percentage Breakdown of Number of Nano-Based Products by Application Area - Drug Delivery, Biomaterials, In Vivo Imaging, and Others (includes corresponding Graph/Chart).....II-5
Nanotechnology Based Drug Delivery Products.....II-5
Table 2: Global Nanomedicine Market (2007): Percentage Breakdown of Number of Nano-Based Drug Delivery Products by Category - Liposomes, Nanocristals, Virosomes, and Others (includes corresponding Graph/Chart).....II-5
1$300
   Nanomedicine Patent Filings.....II-6
Table 3: Global Nanomedicine Market (1993-2003): Percentage Breakdown of Nanomedicine Patents by Application Area – Drug Delivery, In Vitro Diagnostics, Imaging, Biomaterials, and Others (includes corresponding Graph/Chart).....II-6

Table 4: Global Nanomedicine Market (1993-2003): Percentage Breakdown of Patents by Country - US, Germany, Japan, and Others (includes corresponding Graph/Chart).....II-6
1$300
   Nanomedicine - The Future Direction.....II-7
Transforming Healthcare Sector Generating Demand for Nanomedicine.....II-7
1$100
   Nanobiotechnology – A Promising Area.....II-8
High Demand for Tiny Healthcare Devices.....II-8
1$100
   Research in Nanomedicine Continues to Surge.....II-9
Nanotechnology in Healthcare to Sustain R&D Funding.....II-9
1$100
   Nanomedicine Clinical Pipeline to Sustain the Momentum.....II-10
Nanotechnology Gaining Ground in Fast Growing Drug Delivery Market.....II-10
1$100
   Nanotechnology – Generating More Enthusiasm Among Entrants.....II-111$100
   Demand for Supplies and Devices to Grow Rapidly.....II-12
Nanomedicine Needs Analysis of Ethical Implications.....II-12
Nanotechnology-based Drug Delivery Market on an Upbeat.....II-12
Nanotechnology Opens Up New Frontiers in Drug Discovery.....II-12
1$100
   Nanotechnology Raises Hope for Tuberculosis Treatment.....II-13
Demand for Nano-Based Medical Products to Rise Significantly.....II-13
Medical Nanorobotics to Raise the Standards.....II-13
1$100
   Nanomedicine – A Useful Element in Surgical Procedures.....II-14
Nano-based Diagnosis and Medical Imaging Helps Treatment of Critical Diseases.....II-14
1$100
   More Efficient Nanoparticles Could be Made Possible by Modeling Software.....II-151$100
   Major Issues Daunting Nanomedicine Sector.....II-16
1$100
   Nanomedicine - A Primer.....II-17
Nanopores.....II-17
Radio-Controlled Biomolecules.....II-17
1$100
   Quantum Dots.....II-18
Nanotubes.....II-18
1$100
   Fullerenes.....II-19
Nanoshells.....II-19
Nanoprobes.....II-19
Nanoparticles.....II-19
1$100
   Ceramic Nanoparticles.....II-20
Solid Lipid Nanoparticles.....II-20
1$100
   Nanocapsules.....II-21
Dendrimers.....II-21
Liposomes.....II-21
Micelles.....II-21
1$100
   Nanosuspensions.....II-22
Liquid Crystals.....II-22
Hydrogels.....II-22
Polymeric Nanoparticles.....II-22
1$100
   Molecularly Imprinted Polymers.....II-23
1$100
   Drug Delivery.....II-241$100
   Targeted Nanodrug Delivery & Release.....II-25
Active and Passive Targeting Mechanisms in Drug Delivery.....II-25
Sustained and Pulsatile Release Mechanisms in Drug Delivery.....II-25
1$100
   In Vitro Diagnostics.....II-26
In Vivo Imaging.....II-26
Biomaterials.....II-26
Others.....II-26
Drugs and Therapy.....II-26
Active Medical Implants.....II-26
Oncology.....II-26
1$100
   Key Applications in Cancer Therapy.....II-27
Advanced Imaging, Early-Stage Detection, and Targeting.....II-27
1$100
   In-vivo Imaging.....II-28
Effective Tracking of Process Efficiency.....II-28
Advancing Bioinformatics and Proteomics Research.....II-28
Carbon Nanotubes in Cancer Treatment.....II-28
Regenerative Medicine.....II-28
1$100
   Futuristic Applications.....II-29
Bio-molecular Motors.....II-29
Genetic and Tissue Engineering.....II-29
External Tissue Products.....II-29
1$100
   Internal Tissue Implants.....II-30
Dental and Bone Replacement.....II-30
Protein and Gene Analysis.....II-30
Nanorobot Therapeutics.....II-30
1$100
   Lab-on-a-Chip Techniques.....II-311$100
   Medical Diagnostic Sensors.....II-32
Nano Medical Devices – From Surgical Tools to Contact Lenses.....II-32
Nanoengineered Prosthetics.....II-32
Nanotubes – Potential Drug Delivery Vehicles.....II-32
1$100
   Building Blocks of Nanotechnology Used, Components and Final End-Use Products.....II-33
Global Nanotechnology Market.....II-33
1$100
   Table 5: Global Nanotechnology Market (2008 & 2009): Percentage Breakdown of Revenues by End-Use Segments – Chemicals, Automotive, Aerospace & Defense, Semi-Conductors & Electronics, Nanomedicine and Others (includes corresponding Graph/Chart).....II-34
Commercial Applications at an Embryonic Stage.....II-34
1$300
   Recent Commercial Applications of Nanotechnology.....II-351$100
   Nanotech Players – Germany Tops Europe While China Leads Asia-Pacific.....II-36
Table 6: Nanotech Companies in Europe (2007): Number of Players in Major Regional Markets - Germany, United Kingdom, Switzerland, France, and Sweden (includes corresponding Graph/Chart).....II-36
1$300
   Table 7: Nanotech Companies in Asia-Pacific (2007): Number of Players in Major Regional Markets - China, South Korea, Japan, Australia, and Taiwan (includes corresponding Graph/Chart).....II-37
Nanotech Funding by Regional Governments.....II-37
Table 8: Nanotech Funding by Regional Governments (2008): Leading National Markets Ranked by Funding in US$ Million for United States, Japan, Russia, Germany and China (includes corresponding Graph/Chart).....II-37
1$300
   German Scientists Develop Nanoparticle-Driven Gene Transfer Method.....II-38
Oxford Sees Progress in its Novel DNA Sequencing Technology Project.....II-38
Philips Releases First 3D Imaging Findings.....II-38
1$100
   Researchers in University of Pennsylvania Invent Novel Carbon Nanopipette.....II-39
UCLA Scientists Develop Localized and Controlled Drug Delivery Method.....II-39
1$100
   Minerva Makes New Discovery in Cancer Treatment.....II-40
NanoBio Releases Positive Data with NB-002.....II-40
1$100
   NanoBio Receives Positive Pre-Clinical Results with Intranasal Influenza
  Vaccine.....II-41
Abraxis Announces Interim Results of Abraxane® for Metastatic Breast Cancer.....II-41
Abraxis Reveals Positive Data with Abraxane® and Gemzar®.....II-41
1$100
   BioDelivery Commences Clinical Study with Bioral® Amphotericin B.....II-42
NanoCarrier Develops Protein Nanoencapsulation Technology.....II-42
Flamel Releases Positive Preliminary Data from FT-105 Phase I Study.....II-42
1$100
   Abraxis Releases Positive Pre-Clinical Data with nab™ Technology Platform and SPARC
  Expression in Cancer Treatment.....II-43
American Scientists Develop Unique Nano-Based Drug Delivery System.....II-43
Researchers at University of Queensland Focus to Develop Novel Nano-based Diagnostics
  for Cancer Detection.....II-43
1$100
   Indian Researchers Synthesize Polymeric Nanocurcumin for Cancer Therapy.....II-44
Researchers Mull on Using Nanoparticles to Develop Anti-Tumor Vaccines.....II-44
Nanomedicine Creates New Avenues for Regeneration of Nerve Cells.....II-44
1$100
   University of Illinois Develop Enhanced Biomimetic Membranes.....II-45
Johns Hopkins Faculty develop Nanoparticle-Embedded Microcapsules.....II-45
Max Planck Research Team Develops Gold Nanoparticles.....II-45
Nanotechnology based Panacea for Facial Wrinkles.....II-45
1$100
   Starpharma Holdings Releases the NanoJuice™ Transfection Kit.....II-46
Telomolecular Introduces Nano-Based Aging Solution.....II-46
CytoViva® Unveils Advanced Nanotechnology Research Tool.....II-46
1$100
   eBioscience Introduces eFluor™ Brand.....II-47
eBioscience Launches eFluor™ Nanocrystals.....II-47
BioForce Nanosciences Unveils Surface Patterning Service.....II-47
Eastman Kodak Unveils KODAK X-SIGHT Imaging Agents.....II-47
Biomet Launches NanoTite Dental Implant.....II-47
1$100
   Deerac Introduces Equator HTS/2 Liquid Handling Solution.....II-48
IMEC Develops Functionalized Magnetic Nanoparticles.....II-48
Ivoclar Vivadent Introduces New Version of Tetric Flow.....II-48
1$100
   Calando to Begin Human Clinical Trials for siRNA-based Therapeutic Drug for
  Cancer.....II-49
Dabur Pharma Launches Nano-Based Drug Delivery System.....II-49
1$100
   APR Acquires New Drug Delivery Platform.....II-50
Merck Inks Merger Agreement with Schering-Plough.....II-50
Nanobiotix to Collaborate with SonoDrugs Project Consortium.....II-50
Liquidia and Abbott to Jointly Develop siRNA Therapeutics.....II-50
1$100
   Pro-Tect Acquires Medivices’ Nanotechnology Method.....II-51
APR to Create Dedicated Nanotechnology Unit.....II-51
Agilent Takes Over Nano Instruments.....II-51
Veridex Acquires Immunicon.....II-51
1$100
   Thermo Fisher Takes Over nAscent.....II-52
Labcyte and Deerac Fluidics Combine Operations.....II-52
Invitrogen and Applied Biosystems Merge to Form Life Technologies.....II-52
Insert Therapeutics Merges with Calando Pharmaceuticals.....II-52
1$100
   Capsulution Nanoscience and NanoDel Technologies Merge.....II-53
BioForce Forms Collaboration with UAlbany NanoCollege.....II-53
Advion and Bruker Daltonik Enter into Joint Marketing Agreement.....II-53
Midatech Group Inks Agreement with MonoSol Rx.....II-53
1$100
   Advion Signs Co-Marketing Agreement with Agilent Technologies.....II-54
Abraxis Inks Deal to Re-Acquire US Rights to Abraxane.....II-54
NanoKTN and Bio Nano to Develop Nanomedicine.....II-54
Evolved Machines Inks License Contract with Nanosys.....II-54
1$100
   Abraxis Bags European Commission Approval to Market Abraxane.....II-55
Nanogen Eyes European Molecular Diagnostics Market.....II-55
Abraxis Receives Approval for Marketing ABRAXANE in Korea and China.....II-55
BioForce Receives MIT Validation for Nano eNabler Molecular Printer.....II-55
Oxonica and Becton, Dickinson and Co. Sign Strategic Deal.....II-55
1$100
   Nanogen Sells Royalties to DRI Capital.....II-56
Nanogen Signs Deal with Thermo Fisher.....II-56
Midatech Establishes New Nanotechnology Subsidiary.....II-56
1$100
   Nanogen and HX Diagnostics Extend Collaboration.....II-57
CytImmune Joins Hands with University of Maryland.....II-57
Abraxis Inks Licensing Deal with Japan’s Taiho.....II-57
1$100
   Abraxis Files Marketing Application for Abraxane in Japan.....II-58
BioForce Secures State Funding for ViriChip™.....II-58
Capsulution and Advanced Materials Ink Patent License Deal.....II-58
1$100
   Midatech Bags US Grant on Patent Application.....II-59
Nanobiotix Wins European Patent for Activable Particles.....II-59
Nanotherapeutics Submits IND Application for NanoDOX ™ Hydrogel.....II-59
Nanobiotix to Focus on Development of Diagnostics for Tropical Diseases.....II-59
1$100
   Ceres to Develop Novel Nanotechnology Products.....II-60
Batist to Commence Production of Nanotechnology- Based Bandage.....II-60
Unidym Creates Spin-Off Unit.....II-60
1$100
   Avanti Creates Dedicated Targeted Drug Delivery Company.....II-61
Hill-Rom Chooses Anti-Microbial Technology of NanoHorizons.....II-61
Advion Acquires NanoTek.....II-61
Pioneer Surgical Acquires Angstrom Medica.....II-61
1$100
   Arrowhead Acquires C Sixty.....II-62
Veritek Completes Acquisition of Omni-Lite E-Form.....II-62
Wyeth Extends Collaboration with Ablynx.....II-62
Starpharma Inks Agreement with Stiefel.....II-62
1$100
   Nanosys Signs Collaboration Deal with Bruker Daltonics.....II-63
Abraxis Selects Green Cross to Commercialize Abraxane in Korea.....II-63
Abraxis Signs Deal to Partner California NanoSystems Institute.....II-63
1$100
   BioForce Nanosciences Inflates Clientele Base for Nano eNabler™ System.....II-64
Xidex Bags Contract to Make Carbon Nanotube Sources for Electron Microscopes.....II-64
Novartis Extends Deal with Ablynx.....II-64
BioSante Inks License Agreement with Medical Aesthetics.....II-64
1$100
   NanoImaging Launches Imaging Services Unit.....II-65
Midatech Inaugurates cGMP Standard Nanoparticles Production Facility.....II-65
Abraxis Announces Dedicated Proprietary Biotechnology Business.....II-65
1$100
   Eksigent Signs Distribution Deal in Brazil.....II-66
NanoVic Establishes Two Nano-bio Companies.....II-66
Veeco Signs Collaboration Deal with Leica.....II-66
1$100
   NanoViricides Inks CRADA with USDoD Agency.....II-67
Rexahn Wins Maryland Industrial Partnerships Funding.....II-67
Azaya Therapeutics Gains Patent for Nanotech-Based Cancer Treatment Platform.....II-67
Flamel Inks Deal with Wyeth Pharmaceuticals.....II-67
Flamel Signs Deal with Merck Serono.....II-67
1$100
   NanoChip® 400 Platform of Nanogen Now a GSA Schedule Product.....II-68
Nanogen Bags Canadian Funding for Veterinary and Bio-Terror Diagnostics Development
  Project.....II-68
Nanogen Signs Deal in Australia for Schizophrenia Markers.....II-68
1$100
   Wyeth Wins FDA Approval for New Labeling for Rapamune.....II-69
Arrowhead Infuses Capital into Tego.....II-69
GSK Extends Collaboration with Exelixis.....II-69
1$100
   Oncologix Collaborates with Dendritic Nanotechnologies to Redesign its Oncosphere
  Product.....II-70
Abraxis Signs Licensing Contract in India.....II-70
Abraxis Receives Australian TGA’s Acceptance to Review Marketing Application for
  Abraxane®.....II-70
1$100
   Nanotherapeutics and National Cancer Institute Sign CRADA.....II-71
Relisys and Cinvention Extend Licensing Agreement.....II-71
Lumera Extends Collaboration Pact with Medical University of South Carolina.....II-71
1$100
   Abraxis BioScience, Inc. (US).....II-72
Acusphere, Inc. (US).....II-72
Advion Biosciences, Inc. (US).....II-72
Agilent Technologies, Inc. (US).....II-72
1$100
   AMAG Pharmaceuticals, Inc. (US).....II-73
Amgen, Inc. (US).....II-73
Arrowhead Research Corporation (US).....II-73
1$100
   Calando Pharmaceuticals, Inc. (US).....II-74
Nanotope, Inc. (US).....II-74
Tego BioSciences Corporation (US).....II-74
BioForce Nanosciences, Inc. (US).....II-74
1$100
   BioSante Pharmaceuticals, Inc. (US).....II-75
Crucell N.V. (The Netherlands).....II-75
Elan Corporation Plc (Ireland).....II-75
1$100
   Elan Drug Technologies (Ireland).....II-76
Ensysce Biosciences, Inc. (US).....II-76
Enzon Pharmaceuticals, Inc. (US).....II-76
eSpin Technologies, Inc. (US).....II-76
1$100
   Flamel Technologies S.A. (France).....II-77
Johnson & Johnson (US).....II-77
Life Technologies Corporation (US).....II-77
1$100
   Merck & Co., Inc. (US).....II-78
Nanobiotix (France).....II-78
1$100
   NanoCarrier Co., Ltd. (Japan).....II-79
Nanospectra Biosciences, Inc. (US).....II-79
Nanosphere, Inc. (US).....II-79
Nanosys, Inc. (US).....II-79
1$100
   Nektar Therapeutics (US).....II-80
Novavax, Inc. (US).....II-80
Oxonica Plc (UK).....II-80
Par Pharmaceutical Companies, Inc. (US).....II-80
1$100
   pSivida Limited (Australia).....II-81
Starpharma Holdings Limited (Australia).....II-81
Dendritic Nanotechnologies, Inc. (US).....II-81
Starpharma Pty. Ltd. (Australia).....II-81
1$100
   Wyeth Pharmaceuticals, Inc. (US).....II-82
1$100
   Table 9: World Recent Past, Current & Future Analysis for Nanomedicine Market by Application Area – Drug Delivery, In Vitro Diagnostics, In Vivo Imaging, Biomaterials and Other Applications Independently Analyzed with Annual Revenues in US$ Million for the Years 2006 through 2015 (includes corresponding Graph/Chart).....II-831$300
   Table 10: World 10-Year Perspective for Nanomedicine Market by Application Area – Percentage Breakdown of Revenues for Drug Delivery, In Vitro Diagnostics, In Vivo Imaging, Biomaterials and Other Applications for the Years 2006, 2009 and 2015 (includes corresponding Graph/Chart).....II-841$300
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com